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Pemphigus vulgaris (PV) is an autoantibody-mediated blistering mucocutaneous disease driven by 
pathogenic antibodies to desmoglein-1 and -3 (dsg-1, 3), levels of which correlate with disease 
activity. This correlation is said to vary with isotype, with anti-dsg-3 IgG4 antibodies predominating 
in active disease, and IgG1 in remission. However these observations derive from single time point 
studies, with crude assessments of disease activity. Using the validated PV clinical scoring tool 
‘pemphigus disease area index’ (PDAI), the current study sought to re-evaluate the clinical relevance 
of desmoglein autoantibodies, sub-divided by isotype, in the routine management of patients with PV. 
40 PV patients were enrolled, all at various stages of disease activity and treatment. PDAI was 
measured and studied in relation to levels of anti-dsg-1IgG and anti-dsg-3 IgG, the latter divided into 
IgG1 and IgG4 isotypes. 24 of these patients had data from three or more time points over a median 
time period of 15 months (range: 4.5 – 23 months), and were evaluated for correlation with changes 
in clinical activity. 
At study enrolment, only anti-dsg-3 IgG4 levels were significantly associated with PDAI values but 
this association was weak (rank correlation r=0.370, p=0.019). During follow-up, within patient 
changes in PDAI observed across serial samples were significantly associated with serial changes in 
total anti-dsg-3IgG levels, with the strength of these associations being similar for both anti-dsg-3IgG 
isotypes. The study was therefore unable to confirm the predominance of anti-dsg-3 IgG1 during 
remission, nor of anti-dsg-3IgG4 during active disease. Changes in anti-dsg-1 IgG levels did not 
clearly follow changes in PDAI, although most patients were negative at baseline. 
In conclusion, absolute levels of anti-dsg-3 IgG4 correlated weakly with disease activity scores at a 
given time point, with wide individual variation. The study was unable to confirm the reciprocity of 
IgG1 versus IgG4anti-dsg-3 in relation to disease activity in patients with established PV over time, 
however within patient changes in levels of anti-dsg-3IgG, irrespective of isotype, seemed clinically 
useful in following treatment responses. 
12 
 
   
 
 
 
 
 
 
CHAPTER 1 
 
Pemphigus Vulgaris 
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1.1 Introduction 
Pemphigus is a group of chronic autoimmune diseases (Table 1) characterised by intra-epithelial 
blistering, resulting in superficial vesicles or bullae that easily rupture, leading to ulceration of 
mucosal and/or cutaneous sites. The term “pemphigus” is derived from the Greek word “pemphix”, 
which means bubble or blister. Lesions result from autoantibody binding to specific desmosomal 
proteins on the surface of the keratinocytes, resulting in loss of cell-cell adhesion, termed 
acantholysis. Pemphigus vulgaris is the most common and clinically aggressive variant and is 
associated with significant morbidity and mortality.[1] 
 
 
1.2 Clinical Features 
PV commonly presents with oral lesions up to 70% of cases. These lesions may be the initial and 
only sign of disease. Cutaneous lesions tend to develop an average of 5 months after oral involvement 
[2, 3].Commonly, oral mucosal lesions appear as intact fluid filled vesicles and bullae that rupture 
easily. These form tender irregular mucosal erosions and ulcers [1]. Any oral mucosal site may be 
affected however the most common areas include the gingival, buccal and palatal tissues [4]. Most 
lesions are painful and slow healing, although do not tend to scar. Desquamative gingivitis is often 
noted in severe cases where the blisters have ruptured leaving areas of peeling tissue with red 
erosions and ulcers [5].Lesions may spread to involve the oropharynx and larynx. Mucosal tissues at 
other sites such as the conjunctiva, oesophagus, and genitalia may also develop lesions. Cutaneous 
involvement similarly presents as flaccid fluid-filled blisters which rupture easily due to their intra-
epithelial nature, resulting in painful erosions. These lesions arise in normal-appearing skin. A 
positive “Nikolsky sign” is often noted in association with both mucosal and cutaneous lesions, 
wherein blisters may be induced or expanded when lateral pressure is applied to the tissue. 
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1.3 Epidemiology 
The incidence of PV varies amongst populations from 0.1–0.5 patients per 100 000 population per 
year [6], with a mean age of onset between 50 to 60 years of age, although there have been reported 
cases of children and elderly individuals also being affected [7, 8]. There is an approximately equal 
male to female ratio. PV is more prevalent in Ashkenazi Jews, where the population incidence 
increases to 1.6-3.2 cases per 100 000 [9, 10] and people of Mediterranean and South Asian 
background. Within these ethnic groups, there is an association with certain HLA subtypes: HLA-
DR4 (DRB1*0402) seen in Ashkenazi Jews and, DR14 (DRB1*1401) and DQB1*0503 in patients of 
European and Asian backgrounds, respectively [11] Recently, a polymorphism within the pro-
apoptotic molecule ST18 has also been reported in association with PV [12]. 
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Table 1.  Clinical and Immunohistochemical Variants of Pemphigus[13] 
Disease and Subtype(s) 
(alternate terms)       
Clinical Presentation Prognosis/Outcome Target Antigens 
Oral  Cutaneous   
Pemphigus vulgaris (PV) Common. 
Usually the first 
site involved 
Commonest and most aggressive form of pemphigus: oral mucosal involvement 
common and often first site of presentation leading to extensive skin involvement. 
Fatal  if  untreated 
Good with treatment 
Desmoglein 3  
(& Desmoglein 1) 
 Pemphigus vegetans 
Rare  
(in all 3 forms 
of pemphigus 
vegetans) 
Uncommon and less aggressive clinical variant of PV:  presents with large 
verrucous confluent plaques and pustules localized to flexural areas in the axilla 
and groin.  
Often progresses to 
pemphigus vulgaris 
 Pemphigus vegetans  
of Neumann  
Often begins and ends as typical PV.  Needs more intense immune-suppression 
than seen with PV, with patients troubled by chronic relapses (and remissions). 
Frequent relapses 
(even with treatment) 
 Pemphigus vegetans  
of Hallopeau  
Relatively benign, usually very well localised disease.  Prolonged remission 
(with treatment) 
Pemphigus foliaceus (PF) 
Rare 
(all 3 forms of 
pemphigus 
vegetans) 
All forms of PF are characterised by clinically by superficial cutaneous blisters 
and erosions are seen clinically and histologically by subcorneal acantholysis.  
More benign course 
than PV, with 
prolonged remission.   
Desmoglein 1 
 Pemphigus erythematosus  
( “Senear-Usher syndrome”) 
Very rare condition with the combined features of pemphigus foliaceus and SLE 
which manifests with small, flaccid bullae with scaling and crusting confined to 
sun-exposed skin, with lesions of the face presenting in the typical butterfly 
pattern seen in SLE. 
 Endemic pemphigus  
( “Brazillian pemphigus” or 
“Fogo Sevagem” (FS)) 
PF and FS are identical clinically, histologically, and serologically but differs 
significantly, epidemiologically, with marked geographic clustering in Brazil, 
being a diseases of people resident or near the rainforests. Other endemic forms 
of FS have been reported in Colombia, Peru, and Tunisia.  The autoimmune 
response in FS is thought to be triggered by a putative environmental factor.  
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IgA pemphigus 
Rare 
(all 3 forms of 
IgA pemphigus)  
Rare, characterised by pruritic, flaccid vesicles and/or pustules in annular pattern 
with central crusting, sometimes hypopyon (sterile leukocytic exudate, seen in the 
anterior chamber of the eye). Pathogenesis: more directly related to the 
neutrophilic infiltrate in the epidermis rather than solely to the binding of IgA to 
target epidermal antigens.  DIF: IgA (cf IgG seen in all other forms of 
pemphigus)  deposits in lower epithelium or entire epidermal cell surfaces Recalcitrant to 
treatment with 
corticosteroids  
Desmoglein 3  
(& Desmoglein 1)  Subcorneal pustular 
dermatosis (“Sneddon-
Wilkinson disease”) 
Subcorneal (beneath the stratum corneum) blister containing neutrophils with 
epidermal acanthosis and spongiosis, results in superficial fragile blistering. 
 Intraepidermal neutrophilic 
IgA dermatosis 
Deeper, intra-epidermal blister containing neutrophils with epidermal acanthosis 
and spongiosis, results in more marked blistering and consequent ulceration. 
Paraneoplastic pemphigus  
Common & 
very severe 
Polymorphous skin eruption, consisting of blisters, erosions, and targetoid 
lesions; severe mucous membrane involvement.   
DIF: IgG deposits on entire epidermal cell surfaces +/- granular-linear 
complement autoantibodies to rat bladder epithelium in 75% of cases.  
Fatal 
Desmoglein 3, 
Desmoplakin 1, 
Desmoplakin 2,                 
BP 230, evoplakin, 
periplakin, others 
Familial benign  
chronic pemphigus 
(“Hailey-Hailey disease”) 
Rare 
Not a true form of pemphigus, as it is not antibody mediated. 
Autosomal Dominant, it presents a chronic recurrent bullous and vesicular 
dermatitis of intertriginous areas that is characterized histologically by suprabasal 
acantholysis. Cause: heterozygous mutations of the ATP2C1 gene leads to a 
malfunction of the encoded protein hPMR1 -  hPMR1 being a high-affinity 
calcium transport ATPase pump of the Golgi complex. Low levels of intracellular 
Ca2+ induces premature keratinocyte proliferation, which may lead to 
dysfunctional desmosomal proteins and thus abnormal keratinocyte adhesion.  
chronic, relapsing–
remitting course 
Desmocollin 1 
Abbreviations:  PV = pemphigus vulgaris; PF = pemphigus foliaceous, SLE = systemic lupus erythematosus, FS = Fogo Sevagem, DIF = direct immune-fluorescence,  
cf = in contrast, BP = bullous pemphigoid, Ca2+ = calcium ion 
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1.4 Diagnosis  
Biopsy of perilesional tissue demonstrates intraepithelial vesicle formation. Intercellular oedema is a 
relatively early feature, and this is usually accompanied by loss of intercellular attachment in the 
basal layer. “Clefting” may be noted as the suprabasal keratinocytes cells separate from the basal 
cells. The basal cells themselves are separated from each other, forming a “tombstone” appearance at 
the floor of the blister, but these cells remain attached to the basement membrane. Acantholytic 
(Tzanck) cells may be seen within the vesicle [6, 14].  (Fig 1)   
 
Figure 1. Hallmarks of PV. Normal epidermis (A). Suprabasal acantholysis in patient with PV (B). Oral 
lesions and epidermal blistering manifested in PV patients (C) [15]. 
 
 
 
Direct immunofluorescence (DIF) performed on fresh tissue commonly shows a classical “basket 
weave” pattern on staining for IgG, reflecting its deposition on the surface of the keratinocytes. IgM 
and complement components such as C3 are also often present. This pattern is driven by circulating 
IgG autoantibodies that bind to the surface of epithelial cells (‘intercellular cement substance 
antibody’, ICSA) may be detected by indirect immunofluorescence (IIF) in 80-90% of patients with 
PV. Antibody titres may also help guide prognostication and therapy [16], generally reflecting 
disease activity.  
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These antibodies are detected using either primate oesophagus or human skin as the substrate, but 
specificity studies have demonstrated that the main autoantigens are desmoglein 1 and 3 (dsg-1 and -
3)[17-20].  
 
This diagnostic specificity has been improved by using purified autoantigens as substrate on enzyme 
linked immunosorbent assay (ELISA). This assay was developed using human recombinant dsg-1 
and dsg-3 proteins, and detects circulating autoantibodies in pemphigus patients [21], and has been 
shown to be highly sensitive and specific. Studies have shown that ELISA values often correlate with 
pemphigus disease activity [22]. An ELISA method that utilises antigen ectodomains of dsg-1 and 
dsg-3 generated in human HEK293 cells for the detection of autoantibodies anti-dsg-1 and anti-dsg-3 
has also recently become available [23]. 
 
Most studies have suggested that ELISA constitutes a better test for the diagnosis and management of 
PV. Meta-analysis exploring the diagnostic accuracy of the anti-dsg-3 ELISA concluded that with a 
mean sensitivity of 97% and a mean specificity of 98.5%, the high diagnostic accuracy of this test 
afforded greater consistency of diagnosis despite differences in the selection of control groups and 
defining cut off values between studies [24]. No analysis could be performed comparing IIF and 
ELISA methods due to the limited number of studies that have utilised both techniques 
simultaneously. However, analysis of the 6 studies [25-30] that investigated IIF for the diagnosis of 
PV, reported sensitivity values ranging from 74% to 99.9%, values that were equal to or lower than 
the analytical sensitivity of ELISA methods [24]. 
 
 
1.5 Management 
Prior to the advent of corticosteroids the mortality rate for untreated PV patients ranged from 60% to 
90% [10]. Use of steroids and other immune therapies have reduced the rate significantly to 5-15% 
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[31]. However, as with all therapies, there are associated side effects. Currently, the goal of managing 
PV is to induce and maintain remission, using the lowest dose of medication possible, so as to 
minimize such side effects. 
 
Corticosteroids remain the primary treatment for PV patients, due to their ability to rapidly and 
effectively induce remission. The side effects associated with steroid use include weight gain, 
diabetes, osteoporosis, hypertension, immunosuppression, sepsis, and changes to fluid balance[32]. 
Long-term management of these patients almost inevitably requires the introduction of a steroid 
sparing agent, commonly azathioprine or mycophenolate [33-38].     
 
In addition to conventional methods of therapy, there are a number of emerging therapies that have 
been developed over the years, including intravenous immunoglobulin, plasmapheresis, extracorporal 
photochemotherapy, and cholinergic agonists [10, 39-48]. Furthermore, there have been many case 
reports suggesting the use of rituximab, a monoclonal anti-CD20 antibody [47, 49-64] and TNF- 
antagonists (i.e. infliximab and etanercept), in suppressing PV [65-69] 
 
1.6 Prognosis and Outcome 
The natural course of PV is variable as is the severity of the disease. Most deaths occur during the 
first few years of disease, and if the patient survives 5 years, the prognosis is good. Management and 
control of the condition is more straightforward during early, limited disease, whereas widespread 
disease is generally more difficult to control, hence mortality may be higher if therapy is delayed 
[70]. 
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Morbidity and mortality are related to the extent of disease, the maximum dose of 
immunosuppressive therapy required to induce remission, and the presence of other medical co-
morbidities[71]. Complications secondary to the use of immunosuppressive therapy may also 
contribute to the reported mortality rate [71].  
 
Several groups have evaluated laboratory tests for measuring and predicting clinical activity. Levels 
of desmoglein autoantibodies are reported to fluctuate with disease activity, consistent with their 
pathogenic role; thus titres of ICSA [16, 35] and levels of anti-dsg IgG [72-75]tend to fall with 
successful therapy, and rise with relapse. 
 
The incidence and duration of true remission in PV is uncertain[70]. It is unknown whether treatment 
suppresses disease manifestations, and so must be continuously administered, or whether it induces 
complete true remission in some patients, allowing therapy to be discontinued. A recent long-term 
longitudinal study of complete and long-lasting remissions (defined as lesion-free with no systemic 
therapy for at least 6 months) enlisted 40 patients with PV treated conventionally and followed up for 
an average of 7.7 years[70]. The authors reported that five patients (5%) died of the disease but 
complete and long-lasting remissions were induced in 25, 50 and 75% of patients at 2, 5 and 10 years, 
respectively, after diagnosis [70].The majority of the remaining patients were in partial remission or 
had mild disease controlled with a low dose of systemic corticosteroids. The authors concluded that it 
was possible to induce complete and long lasting remissions in many patients, allowing systemic 
therapy to be discontinued without a relapse in clinical disease activity[70].
 
 
1.7 Pathogenesis of Blister Formation 
Patients with PV generate autoantibodies against the desmosomal cadherins, typically dsg-3 and in 
50% of cases, also to dsg-1 [14, 20, 76-79], both of which are adhesion molecules found in stratified 
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squamous epithelium. Dsg-3, a 130kd glycoprotein, is found primarily in the suprabasal layer of the 
epithelium.This antigen-antibody interaction activates complement, releasing inflammatory mediators 
and recruiting activated T cells. Damage to the intercellular area induces apoptosis, loss of cell-to-cell 
adhesion (acantholysis) and eventually intra-epithelial blistering [6]. 
 
The pathogenic nature of dsg-3 specific autoantibodies has been studied and supported by 
observations of various groups who have found that disease activity in PV is mostly correlated with 
dsg-3specific IgG titres in the patients’ sera. Blisters have been observed in newborn babies of 
mothers with active PV as a result of transplacental transmission of maternal dsg-3 specific 
autoantibodies. In addition, pemphigus-like lesions may be induced in neonatal mice following the 
passive transfer of purified serum IgG from patients with active disease [80-82].  
 
It is generally accepted that PV can be classified into two subtypes; the mucosal dominant type with 
mainly mucosal lesions and minimal, if any, skin involvement, and only anti-dsg-3 IgG 
autoantibodies; and the mucocutaneous type in which patients have mucosal and skin lesions, and 
anti-dsg-1 in addition to anti-dsg-3 IgG autoantibodies [25].The clinical manifestations of mucosal 
PV compared with mucocutaneous PV can be explained by the distinct pattern of distribution of the 
two target antigens, dsg-1 and dsg-3, within the epithelia, thus determining the site of acantholysis. 
Dsg-3 is highly expressed in oral epithelium, whereas skin epithelium expresses both dsg-3 and dsg-
1. As such, oral involvement tends to be an early sign of the disease; however, once dsg-1 antibodies 
develop, skin and lesions of other mucosal site develop [6, 20, 22]. 
 
In the related disease, pemphigus foliaceous, in which only skin lesions are apparent, antibodies are 
typically directed against dsg-1 alone [83, 84]. 
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1.8 Desmoglein Compensation Theory  
The mechanism by which blisters form in PV is thought to be related to the autoantibody mediated 
disruption of desmoglein-dependent cell adhesion. However, there is variability in the site of this 
disruption amongst the pemphigus diseases, with PV patients having relatively deep blisters, whilst 
the blisters in PF patients are more superficial, despite both conditions being driven by desmoglein 
antibodies. Distribution of lesions also varies, the lesions in PF being confined to the skin, whilst in 
patients with PV, some have only oral involvement, whilst others have both skin and mucosal lesions.  
The “desmoglein compensation theory” attempts to explain this variability. It proposes that dsg-1 and 
dsg-3 “compensate” for their adhesive function when they are co-expressed in the same cell (Fig. 
2)[85-87]. 
 
This theory is based on the pattern of intraepithelial expression of dsg-1 and dsg-3. In the skin, dsg-1 
is expressed throughout the epidermis, but more intensely in the superficial layers. On the other hand, 
dsg-3 is found to be expressed in the lower section of the epidermis, concentrated in the basal and 
suprabasal layers[77].In mucosae, both dsg-1 and dsg-3 are expressed throughout the epithelium, 
howeverdsg-1is expressed at a much lower level than dsg-3[85]. 
 
Thus, in the presence of anti-dsg-1 IgG, blistering occurs only in the superficial layers of the 
epidermis, as this is the only area in which dsg-1 is expressed without co-expression of dsg-3 (Fig. 
2A); the deeper epidermis remains unaffected due to the adhesive action of dsg-3, thus 
“compensating” for the loss of functional dsg-1. In other words, despite the anti-dsg-1 IgG binding to 
the mucosa, no lesions are noted because of the co-expression of dsg-3. This hypothesis is compatible 
with the clinical findings in PF, where there is formation of only superficial lesions in the skin in 
absence of mucosal involvement.  
23 
 
   
By contrast, in the presence of anti-dsg-3 IgG alone, the co-expression of dsg-1 itself is now able to 
“compensate” for loss of functional dsg-3. Thus there are few if any skin lesions (Fig. 2B). In the 
mucosae, dsg-1 is unable to compensate for the impaired dsg-3 function because of its low expression, 
resulting in the clinical predominance of oral lesions, in the absence of skin involvement, in these 
patients’ PV.  
 
When sera contain both anti-dsg-1 and anti-dsg-3 IgG, the function of both dsg-1 and dsg-3are 
disrupted, resulting in both skin and mucosal lesions, typical of patients with the mucocutaneous type 
of PV (Fig.2C).  
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Figure 2. Desmoglein Compensation Theory [76] 
The triangles represent the distribution ofdsg-1 and dsg-3 in the skin and mucous membranes. PF sera contain 
only anti-dsg-1 IgG and cause superficial blisters in the skin because dsg-3 functionally compensates for the 
impaired dsg-1 in the lower part of the epidermis, while these sera do not cause blisters in the mucous 
membrane because cell-cell adhesion is mainly mediated by dsg-3 (A). Sera containing only anti-dsg-3 IgG 
cause no or only limited blisters in the skin because dsg-1 compensates for the loss of the dsg3-mediated 
adhesion, whereas those sera induce separation in the mucous membrane where the low expression of dsg-1 
will not compensate for the loss of the dsg-3-mediated adhesion (B). When sera contain both anti-dsg-1 and 
anti-dsg-3 IgG, the function of both desmogleins are compromised and blisters occur both in the skin and 
mucous membranes (C). 
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1.9 Anti-dsg- 3 IgG Isotypes 
Several groups have analysed the distribution and role of anti-dsg-3 IgG isotypes at discrete stages of 
disease. In the majority of cases these studies hadsmall numbers of subjects and analysed one, or a 
very limited set of IgG isotypes, often with contradictory results[88]. 
 
There seems to be general consensus that both IgG4 and IgG1 are the most important isotypes in PV 
[28, 75, 89-94]. Some studies provided evidence for a critical role of dsg-3 specific IgG4 in the 
development of PV [28, 95-98]concluding that anti-dsg-3 IgG4antibodies predominate in acute and 
active disease [28, 75, 89-93, 99], whilst anti-dsg-3IgG1 autoantibodies predominate in chronic 
disease and remission [75, 97, 99, 100].That anti-dsg-3 IgG1antibodies may be less pathogenic was 
supported by studies of healthy relatives of PV patients and carriers of PV-related HLA class II 
alleles, who have low levels of dsg-3-reactive IgG1 but remain disease-free [97, 99, 100]. By 
contrast, other studies have found that both isotypes remain elevated during remission [75, 88, 99, 
101].Finally, only two groups have explored other immunoglobulin isotypes beyond the IgG subclass, 
and either observe [94, 99], or do not observe [102]increased levels of antigen-specific IgA and IgE. 
 
These conflicting observations may relate to differences in definitions of disease activity, since 
studies were performed before a validated disease extent tool was available, and might also have been 
limited by the study of patients at only a single time point.  
 
1.10 Scoring Systems 
In recent years, several groups have addressed the need for a standardised, validated outcome 
measure for disease assessment in PV[103]. The PDAI was developed by the International 
Pemphigus Group at a similar time to the Autoimmune Bullous Skin Disorder Intensity Score 
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(ABSIS), developed by the German Blistering Disease Group. When the two scoring systems were 
compared, the PDAI had the highest inter-rater and intra-rater intra-class correlation coefficients 
(ICCs) [104]. A limitation of this study was that most patients had relatively stable disease.  
More recently, Kamiya et al. investigated whether pemphigus disease activity correlated with dsg-3 
titres over time and found that the titres of the conformational dsg-3 epitopes correlated with the 
PDAI score [105]. Patsatsi et al. assessed the disease correlation of PV and PF with anti-dsg-1 and 
anti-dsg-3 ELISA titres using the PDAI and ABSIS systems. They found a statistically significant 
association between the total PDAI or ABSIS scores and dsg-1 titres in patients with cutaneous 
involvement, but only moderate correlation between dsg-3 titres and ABSIS or PDAI scores in 
patients with only mucosal involvement [106].  
 
A third scoring system, the Pemphigus Vulgaris Activity Score (PVAS) was developed and validated 
by Rahbar et al. The study compared all three systems with ELISA scores for dsg-1 and -3, finding a 
higher inter-rater reliability for the PDAI compared with the ABSIS and PVAS. The inter-rater 
reliability remained similar for the PDAI and the PVAS at both high and low dsg titres, whereas for 
the ABSIS, it was less reliable at low dsg titres. High inter-rater reliability was observed for skin 
activity and mucosal activity of the PDAI, followed by skin activity of the PVAS, and then oral 
involvement of the ABSIS. Hence it was agreed that the PDAI was the most useful of the three 
systems [107]. 
 
One advantage of the PDAI is its sensitivity to low numbers of lesions within defined anatomical 
areas, which results in increased inter-rater reliability. By contrast, the ABSIS and PVAS use items 
that make the measures less reproducible. The ABSIS uses the low-agreement rule of nines to 
estimate the percentage of body surface area involvement, which becomes more difficult for limited 
disease activity. Both the ABSIS and PVAS require evaluation of lesion type and apply it as a 
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weighting factor, which exaggerates small differences between raters and causes lower inter-rater 
reliability[103].  
 
1.11 Project Background 
Current dogma suggests that pathogenic ICSAs are of the IgG4 isotype in early disease, but IgG1 
predominates in remission, however despite this widespread belief, results from many studies have 
been inconsistent with this view.  
 
The earliest studies of IgG profiles in PV utilised immunofluorescence techniques [90-93]. In 
general, these groups found that IgG4 was the most prevalent isotype present in PV, followed by 
IgG1. IgG2 and IgG3 were often present however at a significantly lower level. 
 
More recent studies have employed immunoblotting and ELISA techniques. These methods have the 
advantage of being able to distinguish between anti-dsg-3 and anti-dsg-1 antibodies [28, 75, 89, 99, 
100, 102, 108-110]. Many of these studies again found a predominance of anti-dsg -3 IgG4 and IgG1, 
with lower or absent levels of IgG2 and IgG3 antibodies in PV patients [25, 28, 89, 97, 102].  
 
There are, however, conflicting results when immunoglobulin levels are compared between patients 
with active disease and those who are in remission. Several studies found significant predominance of 
IgG4 during the active phase of PV, and IgG1 during times of disease quiescence[75, 89, 99]. 
Contrary to this, several groups observed a predominance of anti-dsg-3 IgG4 during remission [90], 
or reported a decreased, though still detectable, level of IgG4 and IgG1 anti-dsg-3 antibodies, with no 
subclass switch[102]. 
 
The majority of studies did not employ an objective reproducible measure of clinical activity. 
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1.12 Research Description and Hypothesis 
The current project therefore sought to measure anti-dsg-3 IgG isotype changes at various clinical 
stages of PV activity using ELISA-based methods and a validated PDAI scoring tool, and examining 
the hypothesis that the use of PDAI scoring systems, along with a carefully calibrated IgG isotype-
specific ELISA in static and serial samples from PV patients, will support the contention that PV is 
characterised by anti-dsg-3 IgG4 antibodies during its active phase, and by IgG1 during remission. 
 
1.13 Aims 
This study aimed to measure IgG autoantibodies to dsg-1 and dsg-3, the latter divided by isotype, in a 
cohort of patients with PV, both at a single time point during established disease, and then serially, 
using a validated tool for measuring the extent of cutaneous and mucosal disease, in the form of the 
Pemphigus Disease Area Index (PDAI)[104]. 
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2.1 Patient recruitment 
Entry into the study required a clinical diagnosis of PV, supported by the typical histopathology 
changes of suprabasal acantholytic blisters, along with deposition of IgG and usually C3 on the 
intercellular cement substance by direct immunofluorescence microscopy, and positive circulating 
autoantibodies to intercellular cement substance as detected by indirect immunofluorescence using 
primate oesophagus as substrate [94]. Samples were referred for anti-dsg-1 and -3 IgG testing from 
various tertiary referral hospitals around Australia, including Immunology, Dermatology and Oral 
Medicine clinics, and were collected between January 2010 and January 2012. Clinicians supplied a 
PDAI [104] (see appendix) for each sample submitted. Subsequent serum samples were collected at 
review appointments, along with the updated PDAI. 
 
A total of 40 PV patients from seven centres were studied, involving 187 serum samples (24 with 
three or more samples, eight with two serum samples, and eight patients with a single sample). The 
median period of follow-up of the 24 patients with three or more samples was 15 months (range 4.5-
23).Patients with various degrees of disease activity and on various immunosuppressive medications 
were studied, including patients whose disease was restricted to the mucosae and also those with 
mixed skin and mucosal involvement (Table 1). 
 
Serum was stored at -20°C until analysis. ICSA titre results were sourced from a subset of patients 
followed in the Oral Immunology outpatient clinic at Westmead Hospital. These data were used to 
quantify the association between ICSA and anti-dsg-1 and dsg-3 IgG. The study was approved by the 
Ethics Committee at Westmead Hospital (see appendix) 
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2.2 Pemphigus Disease Area Index (PDAI) 
Disease activity was recorded using a validated scoring system termed the PDAI which captures the 
extent and severity of disease and has good inter-rater reliability [104]. Each anatomical area is 
examined and assigned a score based on the number and size of lesions present. A damage 
component is usually incorporated to record areas affected by PV, such as areas of post inflammatory 
hyperpigmentation, but was ignored for the purposes of this study. The total possible disease activity 
scores thus ranged from 0 to 250 points, 120 points for skin activity, 10 points for scalp activity, and 
120 points for mucosal activity. Because the observed distribution of PDAI in our population was 
highly skewed, the transformed variable ‘log10 (PDAI+1)’ was used for statistical analysis and 
graphical representation (See appendix). 
 
2.3 Anti-dsg-1 and dsg-3 IgG ELISA 
ELISAs were performed using the Mesacup Desmoglein Test – Dsg 1 and Dsg 3 ELISA kits (MBL 
International, Japan) according to the manufacturer’s instructions. Briefly, recombinant purified Dsg- 
1 and- 3 autoantigen-coated wells were incubated for 60 minutes at room temperature with 100µl 
patient serum diluted with Tris buffer, bovine serum and 0.09% sodium azide to a concentration of 
1/101. Manufacturer supplied negative calibrator (normal human serum with Tris buffer, bovine 
serum and 0.09% sodium azide) and positive calibrators (anti dsg-1 antibody positive human serum 
with Tris buffer, bovine serum and 0.09% sodium azide and anti-dsg-3 antibody positive human 
serum with Tris buffer, bovine serum and 0.09% sodium azide , for dsg-1 and -3 ELISA kits 
respectively) were also included. Wells were washed with a solution of PBS and Tween 20and then 
bound IgG was detected by adding 100µl of conjugate (horseradish peroxidase conjugated mouse 
monoclonal anti-human IgG diluted with HEPES and bovine serum albumin to a concentration of 
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1/101) to each well before incubation at room temperature for 60 minutes. Following a second wash 
stage, binding of this conjugate was developed by a 30 minute incubation at room temperature with 
3,3’,5,5’-tetramethylbenzidine dihydrochloride/hydrogen peroxide (TMB/H2O2). The reaction was 
stopped by the addition of 100µl 1.0N sulphuric acid to each well. The optical density (OD) was 
determined using an automated microplate reader with absorbance read at a wavelength of 450nm 
(a450). Results were calculated by the following formula: 
Unit value (U/ml) = ( a450<sample> - a450<calibrator 1>)     x100 
                   (a450<calibrator 2> - a450<calibrator 1>)      
Where “calibrator 1” was the supplied positive calibrator, and “calibrator 2” was the supplied 
negative calibrator.  
OD values were translated to Units/mL with reference to a kit calibrator preparation designated to 
have 100 Units, using a single point standard curve. Quality control was provided by using a negative 
control (normal serum) as well as a known positive sample, diluted to a value of approximately 20 
U/ml. Repeat values were within two standard deviations; assay runs yielding a variation greater than 
this were discarded, and the run repeated ((Fig 3). In addition, for the assay to be deemed valid, the 
following manufacturer’s criteria needed to be met:  
A450 of Calibrator 1: ≤0.100 
A450 of dsg-1 (or dsg-3) Calibrator 2: ≥0.700 
The assay range for the kit according to the manufacturer was 5–150 U/ml, a value exceeding 20 
U/ml deemed to be positive. A value exceeding 150 U/ml was re-run in dilution, until a valid result 
that lay within the working range of the assay was obtained [111]. 
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Figure 3. Quality control graphs. 
Quality control was provided by using a negative control as well as a known positive sample, diluted to a value 
of ~20 U/ml. Repeat values were within two standard deviations; assay runs yielding a variation greater than 
this were discarded, and the run repeated. 
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In order to determine the anti-dsg-3 IgG isotypes, this ELISA was modified by using isotype-specific 
antisera as the detection reagent (mouse anti-human IgG1 or IgG4, labelled with horseradish 
peroxidase, 1 mg/mL, Invitrogen, Camarillo, California, USA). Conditions were optimised via 
checkerboard titration, the final working dilution being 1:1000 for anti-IgG1, 1:4000for anti-IgG4. A 
positive calibrator for each isotype was established using a strongly positive patient serum sample; 
this sample was deemed to constitute a value of 100 U/mL, and was aliquotted, frozen and stored at -
80°C to be used in each assay run. As above, separate internal controls for anti-dsg-3 IgG1 and IgG4, 
with a unit value of approximately 20 U/ml, were included, and the run was repeated if the internal 
control value was outside two standard deviations of the mean (Fig 3). A reference range was 
established by assaying sera from 20 normal controls, with the cut-off determined by mean plus three 
standard deviations. From this, a value of >2U/ml was considered positive. 
 
2.4 Indirect Immunofluorescence 
Serum samples of patients followed at Westmead Hospital also underwent testing by indirect 
immunofluorescence, performed by standard methodology. Briefly, serum was diluted 1:10 in 
phosphate-buffered saline (PBS), and 50 µL was added to a substrate of monkey oesophagus (The 
Binding Site, UK) and incubated for 30 minutes at room temperature. Slides were then washed with 
PBS and incubated with anti-human IgG-FITC conjugate (The Binding Site, UK) for 30 minutes, 
shielded from light. After another wash with PBS, slides were set with mounting medium and read 
immediately by fluorescence microscopy. A positive ICSA was characterised by linear staining 
around the cells of the epithelium, an appearance referred to as a "chicken wire" or "snakeskin" 
pattern. Samples displaying an ICSA pattern were subsequently titrated in four-fold dilutions up to 1: 
2560. 
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2.5 Statistical analysis 
The statistical software packages SPSS version 20 and SPLUS version 8 were used to analyse the 
data. Two-tailed tests with a significance level of 5% were used throughout. Individual patient profile 
plots of log-transformed data were used to illustrate the within-patient associations between anti-dsg 
ELISA results and PDAI. Spearman rank correlation (r) was used to quantify the association between 
variables of interest. Rank correlations calculated using three or more serial measurements within 
each subject were summarised by the mean of the within subject rank correlations and its 95% 
confidence interval (CI) and tested for departure from zero using one-sample t tests. 
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3.1Patients 
A total of 40 PV patients from seven centres were studied and included those whose disease was 
restricted to the mucosae and also patients with mixed skin and mucosal involvement (Table 2). 
Patients had various degrees of disease activity and were on various immunosuppressive medications 
at the time of evaluation. 
 
Mucous Membrane only Mucous Membrane and Skin Total 
1-2 samples ≥3 samples 1-2 samples ≥3 samples 
6 12 10 12 40 
Table 2. Subtypes of PV disease in the cohort studies. There were no patients whose disease was 
limited to the skin. 
 
3.2 Only anti-dsg-3 IgG4 levels correlated with disease activity at recruitment 
The relationship between levels of serum anti-dsg IgG and disease activity was explored by plotting 
the log10 (PDAI+1) against ELISA results for anti-dsg-1 (total IgG) and for anti-dsg-3 (total IgG, IgG1 
and IgG4) on entry into the study (Fig 4). Anti-dsg-1 IgG levels were positive only in patients with 
active disease, whereas anti-dsg-3IgG results were positive in most patients, most likely reflecting the 
universal mucosal involvement in this cohort (Table 2). A wide variation in anti-dsg-3IgG values for 
a given level of disease activity was found (Fig 4B), but no significant rank correlation between 
either anti-dsg-1 IgG (Fig 4A) nor anti-dsg-3-IgG and disease activity scores (Fig 4B) was found. 
However, after dividing the anti-dsg-3 specificity by IgG isotype, there appeared to be a weak 
positive association (r=0.370, p=0.019) between levels of anti-dsg-3IgG4 and disease activity at 
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enrolment (Fig 4D). However the study was unable to confirm a significant relationship between anti-
dsg-3 IgG1 and disease activity, with no suggestion of a predominance of anti-dsg-3 IgG1 with 
falling disease activity scores (Fig 4C). 
 
Given the pathogenic relationships between anti-dsg-1 and skin disease, and anti-dsg-3 and mucosal 
disease, the next step was to separate PDAI values into these two component parts, however no 
significant rank correlation between anti-dsg-1 IgG values and skin/scalp PDAI scores (r=0.226, 
p=0.161), nor between anti-dsg-3 IgG values and mucosal PDAI scores (r=0.101, p=0.535), was 
observed. 
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Figure 4. 
Pemphigus vulgaris: The log10 (PDAI+1), plotted against ELISA values for A. dsg-1 total IgG; and for B. dsg-
3 total IgG; C. dsg-3 IgG1 and D. dsg-3 IgG4; at recruitment of the 40 patients in the full cohort. Spearman 
rank correlation (r) and associated p-value are shown. Normal range values for anti-dsg-1IgG and anti-dsg-
3IgG are shaded; the normal range was 0-2 U/mL for anti-dsg-3IgG1 and 4. 
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3.3 Changes in anti-dsg-3 IgG reflected changes in disease activity 
Notwithstanding the poor correlation between anti-dsg antibody results and PDAI at enrolment (Fig 
4), it was important to examine the relationship between and changes in autoantibody levels and 
changes in disease activity over time. Data was plotted from 32 patients who had two or more anti-
desmoglein estimations performed at different time points (Fig 5), and Spearman rank correlations 
were calculated within each of 24 patients who had had three or more estimations (Fig 6). Within-
patient changes in levels of anti-dsg-3 IgG had a moderate to strong statistically significant positive 
association with changes in disease activity in a majority of patients (Figs 5, 6 r=0.325, p<0.001), 
with the rank correlation with disease activity being similar for IgG1 and IgG4 isotypes (Fig 6);thus 
there did not appear to be any clear superiority for any one anti-dsg-3 IgG assay over the others, 
although the sample size was too small for firm conclusions. The relationship between anti-dsg-3IgG 
and disease activity also held true when the PDAI was restricted to just the mucosal component 
(r=0.410, p=<0.0001). 
 
By contrast, within-patient changes in anti-dsg-1IgG showed poor association with changes in PDAI, 
which failed to reach statistical significance (Fig 6, r=0.151, p=0.1395), although patients in our 
cohort had levels that were largely within the reference range. A similar lack of association applied 
when within-patient changes in anti-dsg-1 IgG values were compared with changes in just the 
skin/scalp component of the PDAI scores (r=0.081, p=0.219). 
 
3.4 ICSA titres correlated with anti-dsg-3-IgG levels, and reflected disease activity 
In routine practice, ICSA titres are often used to monitor disease activity in pemphigus, hence it was 
important to determine the overlap between ELISA results and ICSA titres in the assessment of 
patients with PV in this study. To do this, data from the 14 patients enrolled at Westmead Hospital 
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were analysed. This confirmed the positive rank correlation between ICSA titre and disease activity 
at recruitment (Fig 7A, r=0.802, p=0.001), and between the ICSA titre and dsg-3 IgG values (Fig 7B, 
r=0.680, p<0.001). However since only 12 of these patients had three or more ICSA estimations, 
meaningful investigations of within-patient rank correlations could not be completed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 
 
   
 
 
Figure 5. 
Pemphigus vulgaris: The log10 (PDAI+1), plotted against ELISA values for A. anti-dsg-1 IgG; B. for anti-dsg-
3 IgG; C anti-dsg-3 IgG1; and D. anti-dsg-3 IgG4, for the 32 patients who had two or more serial samples 
analysed. Each coloured line represents a single patient. Normal range values for anti-dsg-1 IgG and anti-dsg-3 
IgG are shaded; the normal range was 0-2 U/mL for anti-dsg-3 IgG1 and 4. 
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Figure 6. 
Pemphigus vulgaris: Mean within-patient Spearman rank correlations (r) between PDAI and ELISA values for 
dsg-1 (total IgG) and for dsg-3 (total IgG, subclasses IgG1 and IgG4) in 24 patients with three or more 
assessments during follow-up, and associated 95% confidence intervals. 
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Figure 7. 
A. Pemphigus vulgaris: The log10 (PDAI+1), plotted against ICSA titres at recruitment of the 14 patients in the 
Westmead cohort. 
B. Pemphigus vulgaris: Relationship between ICSA titres and dsg-3IgG levels in the Westmead cohort at all 
stages of follow-up. 
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PV is a classic autoantibody-driven disease in which serum concentrations of pathogenic 
autoantibodies vary in proportion to disease activity, meaning that total IgG autoantibody levels could 
be used as an indicator of clinical response to immunosuppression. However there has been varied 
opinion as to whether IgG isotypes might better reflect this activity. Thus whilst a number of studies 
have found that anti-dsg-3 IgG4 seems to be the predominant isotype during the active phase of the 
disease, and anti-dsg-3 IgG1 during remission, other groups have found no clear relation. 
The present study comprised 40 patients with confirmed PV, 32 of whom were followed over a 
period of time, and found considerable complexity to this relationship when disease activity was 
measured carefully using a graded activity scale, and when autoantibody levels were isotyped and 
carefully standardised. 
 
Three novel observations were made (i) there was poor correlation between anti-desmoglein antibody 
levels and disease activity at a single time point; (ii) within-patient variations in disease activity was 
reflected by anti-desmoglein levels; and (iii) there was no obvious isotype-specific effect in this 
relationship.  
 
1. There was poor to no correlation between the level of anti-desmoglein antibody and the 
contemporaneous disease activity index, with only the levels of anti-dsg-3 IgG4 reaching 
significance, albeit weak (Fig 4). Several studies have previously investigated the relationship 
between clinical disease activity and anti-dsg-3 IgG subclass distribution, with mixed results. Some 
of this variation could be related to differences in the measures of clinical activity used. Many of 
these studies grouped their cohort into clinically active or remittent disease [75, 88-90, 100], whilst 
others further divided the clinically active patients into acute onset and chronic active groups [94, 
99]. The disadvantage of this segregated approach is that there is wide variation in the activity of 
disease within the active groups, with no distinction between patients with mildly active disease and 
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those with more widespread activity. Further, definitions of clinical categories varied between 
groups. Dhandha et al. included patients in the “active” group if their lesions lasted more than a 
week[88], however other studies divided their cohort into “acute onset” and “chronic active” groups. 
The former was defined as “de novo development of lesions on previously unaffected mucosal 
surfaces” in one study[99], however patients participating in another study needed to have cutaneous 
involvement of less than 3 months[94]. Similar discrepancies between studies were noted for patients 
included in the “chronic active” group, which was defined as “expansion/persistence of existing 
blisters on mucosal surfaces” by one study[99], however for patients enrolled in a different study to 
be included in this disease category group, lesions needed to be present for longer than 3 months [94]. 
 
Similarly, the definition of “remission” differed between studies. Dhandha et al. defined this as the 
“absence of new or established lesions for 1-2 months” [88]however Kricheli et al. only included 
patients in this category if they had “no clinical symptoms for at least 6 months” [100]. In addition, 
some groups required that patients in remission have had “no lesions during the 2 or more months 
prior to study” [94, 99], and yet another study required patients to have “no clinical disease off all 
treatment for a minimum of 3 years” [75]. 
 
The advantage of the previously validated PDAI, as used in the present study, is that a clear, objective 
and precise measure of clinical disease activity can be taken for each patient at each time point, 
allowing for more detailed comparison between time points. Thus, a wide spectrum of disease 
activities is measurable by the PDAI, allowing a closer evaluation of the relevance of autoantibody 
levels at any degree of clinical severity. Whilst expecting a stronger association between disease 
activity and anti-desmoglein antibodies, casual observation of Fig 4 reveals that this was far from the 
case; rather, a wide scatter of antibody levels was seen for any level of disease activity. This 
particularly applied to the anti-dsg-3 isotypes, although less can be made of the anti-dsg-1 antibody 
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levels due to low numbers of positives, itself reflecting the predominantly mucosal disease in the 
patients in our study (Table 2). Nevertheless, the small number of patients who did have a positive 
anti-dsg-1 antibody had very active disease. Overall, however, our findings point to wide individual 
variability in absolute levels of anti-desmoglein antibodies and resultant disease. 
 
2. The second major finding here was that within-patient changes in autoantibody levels during 
follow-up did indeed reflect changes in disease activity as measured by the PDAI. The within-patient 
rank correlations between PDAI values and anti-dsg-3 IgG levels were significantly greater than zero 
and indicated moderate levels of association (average r~0.5) (Fig 6). In other words, whilst the 
absolute level of autoantibody generally correlated poorly with measures of disease activity (Figs 
4&5), changes in anti-dsg-3 IgG levels within individual patients were far more useful in reflecting 
changes in disease activity. Although the same did not apply to anti-dsg-1 IgG, the paucity of anti-
dsg-1 IgG positive patients may have reduced our ability to detect an association, since others have 
found a positive correlation in both PV and PF [73, 112]. 
 
3. Perhaps the most important finding here was that there appeared to be no isotype effect in these 
serial studies, with similar within-patient rank correlations for total anti-dsg-3 IgG, anti-dsg-3 IgG1 
and anti-dsg-3 IgG4 (Fig 6). These derivations therefore contrasted with a number of other groups 
who suggested that anti-dsg-3 IgG4 predominates with recent onset of disease, whilst IgG1 
predominates in remission [75, 89-92, 97, 113]. Thus, whilst it was expected that a trend to falling 
levels of anti-dsg-3 IgG4 and rising levels of anti-dsg-3 IgG1 as disease activity decreased would be 
observed, no such effect was apparent (Fig 5).  
 
This discrepancy may relate to methodological differences. The earliest studies of IgG profiles 
utilised immunofluorescence techniques[90-93]. In fact, the majority of early studies utilising 
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immunofluorescence techniques concluded that IgG4 was the most prevalent isotype present in PV, 
followed by IgG1. IgG2 and IgG3 were often present however at a significantly lower titre. For 
example, David et al. included a total of 27 patients, 13 of whom were in the active phase of disease, 
and 14 who were classified as in clinical remission of at least 6 months duration (either off treatment 
or on a maintenance dose of oral steroids), using DIF of fresh skin biopsies of their readout. This 
group found that IgG1 and IgG4 were the most common isotypes in activity and remission; IgG1 was 
found in 100% of active patients and 50% of patients in remission. IgG4 was noted in 85% of patients 
with active disease decreasing to 79% of remittent patients. They concluded that IgG1 was the most 
sensitive indicator for active disease and that IgG4 was the most common isotype found in remission. 
It should be noted that this study was performed on skin biopsy samples, rather than oral mucosae. In 
addition, this was a single time point study, with no serial samples [90].  
 
By contrast, Jones et al. used IIF to analyse serum samples from 8 PV patients at a single time point. 
They found IgG4 to be present in all samples. In addition, IgG1 was noted in 90% of samples at a 
seemingly lower titre to IgG4. No information regarding the patients’ stages of disease was 
included[91].Yamada et al. also found that IgG4 was dominant in active PV. This group utilised both 
DIF and IIF and included 16 PV patients, presumably during the active phase of disease, as samples 
were collected prior to the commencement of therapy. Similar to previous studies, this group only 
analysed a single time point, finding that IgG4 was present in 100% of samples, and IgG1 in 
41%[93]. Other groups used IIF to measure autoantibody levels of the various anti-dsg IgG 
subclasses [28, 90, 91, 93, 94, 100]. Unfortunately, but lack of standardisation of titrations across 
these studies, make direct comparison between groups difficult.   
 
The disadvantage of both DIF and IIF is that the methods are only qualitative (ie either positive or 
negative) or at best only semi-quantitative. This is particularly the case with DIF [90, 93, 94], where 
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it is difficult to measure fluorescence objectively, with authors grading intensity as negative, weakly 
positive or strongly positive. Such studies are difficult to reproduce, making comparison between 
studies very difficult.  
 
More recent studies have employed Western blotting[28, 75, 99, 100, 113] to measure anti-dsg-3 IgG 
isotypes in patient serum. Immunoblotting measures the presence or absence of each IgG isotype, but 
again does not provide a quantitative result. This technique also reveals epitopes in denatured 
proteins, and therefore it is possible that some conformational epitopes of the PV antigen may not be 
detected. One of the earliest studies employing this technique was conducted by Bhol et al., who 
enrolled 27 PV patients with active PV and 13 PV patients in remission, along with a large number of 
healthy controls, samples being taken at a single time point. The authors found that both IgG1 and 
IgG4 were present during active disease, and lower titres of autoantibody, mainly IgG1, were noted 
during remission. This led them to suggest that IgG1 was probably a non-pathogenic antibody given 
its continued presence during clinical quiescence and that IgG4 was most likely the pathogenic 
antibody in PV[75]. 
 
Kricheli et al. included 25 PV patients as well as 55 healthy first-degree relatives and 56 healthy 
controls. Of the PV patients, 13 had active disease and 12 were in clinical remission, defined as the 
absence of clinical symptoms for at least 6 months. The main objective of this study was to compare 
the distribution of IgG subclasses in PV patients and their healthy relatives, however the isotype 
distribution within the PV group was also reported. In this single time point study, investigators 
found no statistically significant difference between active patients and those in remission for anti-
dsg-1 and -3, irrespective of the four subtypes. Similar to the immunofluorescence studies, the 
authors only analysed samples from a single time point. The authors attributed the heterogeneity of 
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results from previous studies to the small number of patients and differences in their clinical status, as 
well as laboratory methodology[100].  
 
A larger study by Spaeth et al. used immunoblot to analyse single time point serum samples from 41 
PV patients and 10 healthy controls. Of the PV patients, 15 of these had acute onset disease, 
including 9 with mucocutaneous lesions; 18 were in the chronic active phase, which included 5 
patients with mucocutaneous disease; and 8 patients in remission. The authors concluded that IgG4 
was the major IgG subtype in both acute onset and chronic active PV. Dsg-reactive IgG1 and/or IgG3 
were detected in the majority of sera from patients in remission. They concluded that the titre of total 
IgG reactivity against dsg-3, including both IgG1 and IgG4 isotypes, might represent useful markers 
to monitor disease activity[99]. 
 
The most recent studies investigating autoantibody isotype profiles in PV have utilised ELISA. Futei 
et al. included 30 PV patients, at “active, mild or moderate stage”; which was otherwise not defined. 
Sera from different time points of active, moderate and mild or remission stages were also obtained 
from a subset of 6 of the PV patients. Disease activity was assessed subjectively by the description of 
clinical findings gleaned from the clinical records. The authors reported ELISA results using OD 
values, and found anti-dsg-3 IgG4 in all samples, and anti-dsg-3 IgG1 in 83% of samples. In the 
serial samples, the authors observed that IgG4 was the predominant subclass throughout the course of 
disease with no subclass shift observed. In the majority of patients, IgG4 titres showed a certain 
degree of fluctuation with disease activity. IgG1 was positive in most patients, however only one case 
showed prominent fluctuations with disease activity. The authors suggested that the higher sensitivity 
of the subclass ELISAs, compared with the total IgG ELISA, may have been important in generating 
these results. They attributed this higher sensitivity to the use of an extra stage of detection, 
consisting of anti-IgG subclass antibody as a second antibody and, in their case, anti-mouse IgG 
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antibody as a third antibody. This high sensitivity may have therefore been useful to detect low levels 
of PV antibody. This study also used IIF to analyse the sera of 12 PV patients, with the majority of 
samples being positive for IgG1 and IgG4, with the latter showing stronger staining[102]. 
 
Hacker et al. used various laboratory techniques including ELISA to analyse the serum from 17 PV 
patients, 7 of who had mucosal disease, and 10 with mucocutaneous involvement at a single time 
point. However no record of the clinical activity of these patients was made at the time of serum 
sampling. ELISAs were performed using the same commercially available kit as the present study, 
and modified for subtype studies, but all ELISA results were reported as OD values. This group 
found that the majority of patients with mucosal disease produced both anti-dsg-3 IgG1 and IgG4. 
Two patients produced only IgG4, and one patient produced IgG3 as well as IgG1 and 4. Patients 
with generalized disease produced both anti-dsg-1 and- 3 antibodies[28]. 
 
In-house ELISA was utilized by Ayatollahi et al. who included single time point serum from 17 
highly active PV patients who had extensive skin erosions and oral cavity involvement, as well as 20 
patients in remission. They found that anti-dsg-3 IgG1 and IgG4 were significantly elevated in active 
patients compared with healthy controls. In addition, anti-dsg-3 IgG1 was significantly elevated in 
remission compared to controls. As with previous studies, ELISA results were reported in terms of 
OD[89].  
 
A more recent large study by Nagel et al. enrolled 93 PV patients: 37 of whom had acute onset 
disease,42 with chronic active disease, and 14 patients in remission. Most patients had 
mucocutaneous involvement (54%), with the remained divided roughly equally between those with 
mucosal or cutaneous-predominant lesions. Samples were taken at a single time point, used in-house 
ELISAs, and reported results in terms of OD. The authors noted that in their study populations, 
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patients with acute onset PV showed the highest concentrations of anti-dsg-3 IgG4, which were 
significantly lower in patients in remission[94].  
 
The most recent study by Dhandha et al. included a total of 71 patients with PV, with 169 samples. 
Patients with non-transient lesions (ie lesions lasting more than a week) were classified as having 
active disease, and those with an absence of new or established lesions for 1-2 months were classified 
as in remission. Contrary to other studies that suggested that the IgG1/G4 ratio was significantly 
elevated in remittent disease when compared to active disease, allegedly resulting from a faster 
decline of IgG4 than G1 in remission, this study showed a greater decrease in the amplitude of anti-
dsg- 3 IgG4 than IgG1, leading to a drop in the relative amount of anti-dsg-3 IgG4 versus IgG1, but 
not in a reversal of the IgG1/IgG4 ratio between disease phases. This study included a large patient 
population with serial samples, however did not use a validated clinical scoring system. ELISA index 
values were used rather than OD to report results, along with appropriate positive and negative 
controls allowing for comparable results from different assay time points [88].  
 
Most studies that utilised ELISA[28, 75, 88, 89, 94] reported results in terms of OD. In one 
study[28], results were only classified as either positive or negative based on an OD cut off. As OD is 
not a standardised calibrated reference, there is inherent inaccuracy with no clear way of comparing 
the reported results between various study groups. To overcome this inaccuracy, all ELISAs 
performed in the current study were calibrated by a standard reference serum, which remained 
constant throughout all assays. All assay results were reported in a numerical value (U/ml) which is 
calibrated to allow accurate comparison between samples. This in turn, allows more meaningful 
analysis of within-patient serial samples. 
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The majority of studies that have investigated anti-dsg-3 IgG isotype distribution in PV have only 
analysed serum at a single time point. Those studies (Futei et al. and Dhandha et al.) that included 
serial samples did not observe a subclass shift between active disease and remission[88, 102], 
consistent with the findings of the present study. Also, similar to the present study, these studies [88, 
102] noted fluctuations in anti-dsg-3 IgG1 and IgG4 titres that follow the clinical course of the 
disease. These studies found that IgG4 was the predominant isotype during both active and remittent 
phases, with fluctuations in this titre reflecting the course of the disease more closely that IgG1 in the 
majority of their cohort. This led to the authors to conclude that anti-dsg-3 IgG4 titres were a better 
indicator of disease activity than any other isotype. This conclusion was not supported by the present 
study, where no single isotype was found to be a superior indicator of disease activity. This 
conflicting observation could possibly be explained by the difference in study methodology and the 
way in which the results were analysed. Futei et al. divided the study cohort into three groups; active, 
moderate, and mild or remission, serial samples were collected from only six subjects[102].  
Therefore, the study of anti-dsg-3 IgG isotype titre fluctuations correlating to disease activity was 
limited by relatively small sample size. Dhandha et al. divided their cohort into two broad disease 
categories; active and remittent disease. The breakdown of disease severity in the active group was 
not stated clearly[88]. Neither of these studies used a standardised scoring system to assess disease 
activity, thereby affecting the ability to accurately correlate disease activity with the isotype titres. 
 
The present study therefore constitutes the most comprehensive of those published so far. Here, PV 
patients were assessed using a previously validated disease activity score (PDAI) allowing serial 
measurements to be correlated with serial measurements of the patient’s antibody levels. This allows 
for smaller differences in clinical activity to be recorded and correlations between changes in disease 
activity and fluctuations in autoantibody titres to be analysed, and firm conclusions to be made, 
namely that although anti-dsg-3 IgG levels correlated poorly with disease activity at a single time 
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point, they did reflect within-patient disease course. Furthermore, no single isotype is superior to 
another in indicating clinical activity. 
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Table 3.Summary of previous anti-dsg-3 IgG isotype studies 
Author PV  Categories Serial Samples Method Results 
David 1989 27 13 active         
14 remission 
No DIF 
IIF 
 
• Anti-dsg-3 IgG1 and IgG4 most common in activity and remission.  
• IgG1 most sensitive indicator for active disease.  
• IgG4 most common isotype in remission 
Jones 1988 8 No information No IIF 
 
• Anti-dsg-3 IgG4 present in all samples.  
• Lower titres of IgG1 in 90% of samples 
• IgG1 not present in 10% of samples 
Yamada 1989 16 16 active No DIF         
IIF 
 
• Anti-dsg-3 IgG4 present in 100% 
• IgG1 present in 41% 
Bhol 1994 40 27 active       
13 remission 
No Western blot 
 
• Anti-dsg-3 IgG1 and IgG4 present in active disease 
• Lower titres of both, but mainly IgG1, in remission 
Kricheli 2000 25 13 active       
12 remission 
No IIF    
Western blot 
 
• No difference in anti-dsg-3 isotypes between active and remission groups 
Spaeth 2001 41 15 acute onset  
18 chronic active 
8 remission 
No Western blot 
 
• Anti-dsg-3 IgG4 dominant in acute onset and chronic active groups. 
• IgG1 detected in majority of patients in remission 
Futei 2001 30 Active, Moderate, 
Mild or remittent 
Yes 6 patients IIF     
ELISA 
 
 
• Anti-dsg-3 IgG4 found in all samples, and predominant throughout disease 
• IgG1 found in 83% 
• No subclass shift 
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Hacker 2002 14 No information No IIF    
Western blot 
ELISA 
 
• Anti-dsg-3 IgG1 and IgG4 present in majority of patients with mucosal 
disease 
Ayatollahi 2004 37 17 active       
20 remission 
No ELISA 
 
• Anti-dsg-3 IgG1 and IgG4 elevated in active patients compared with 
controls 
• IgG1 elevated in remission compared with controls 
Nagel 2010 93 37 acute onset  
42 chronic active  
14 remission 
No IIF        
DIF    
ELISA 
 
• Anti-dsg-3 IgG4 found in highest concentrations in active onset patients 
• Significantly lower levels found in remission 
Dhandha 2012 71 Active    
Remission 
Yes ELISA 
 
• The ratio of anti-dsg-3 IgG4 to IgG1 titres decreased between active and 
remittent phases 
• No reversal in the ratio of these two isotypes between disease phases 
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It should be noted that the present study was not specifically designed to compare new-onset, versus 
chronic and remittent disease, which typical focus of earlier studies, but rather examined all stages of 
disease activity based on PDAI. This approach thus addressed a more ‘real-world’ management 
question.  
 
Finally, on a theoretical basis, the relationship between decreasing disease activity scores and 
decreasing total anti-dsg-3 IgG (Figs 5B &6), would argue against the proposition that a rising 
subtype (such as anti-dsg-3 IgG1) might predominate during disease remission, where one would 
expect stable anti-dsg-3 levels, with alterations in the relative proportions. 
 
The sub-study of patients who had had ICSA performed in a central diagnostic laboratory confirmed 
a correlation with disease activity scores (Fig 7A), and with anti-desmoglein levels (Fig 7B), 
suggesting that ICSA remains a valid laboratory test for assessing treatment responses. Nevertheless, 
the test is only semi-quantitative, making the anti-dsg ELISAs arguably more useful in this regard. 
There was however a wide range of anti-dsg-3 IgG levels for a given ICSA titre (Fig 7B), and this, 
along with a smaller sample size in the ICSA cohort, might explain the discrepancy between the lack 
of significant association between PDAI and anti-dsg-3 IgG levels at enrolment (Fig 4) despite 
significant rank correlation with ICSA titre (Fig 7). 
 
In conclusion, the present study has demonstrated the utility of monitoring changes in anti-dsg-3 IgG 
levels, in following response of PV to treatment. There appeared to be limited utility for measuring 
anti-dsg-3 IgG4 levels in predicting clinical activity at a single time point, and no benefit in 
differentiating anti-dsg-3 by isotype in following disease response over time. These findings should 
assist the interpretation of anti-desmoglein antibody results in the clinical management of patients 
with PV. 
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